Acetaminophen Codeine
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
- Acetaminophen Codeine
- Acetaminophen + Codeine: Evaluation Incomplete — No Repurposing Prediction Available
Acetaminophen + Codeine: Evaluation Incomplete — No Repurposing Prediction Available
One-Sentence Summary
Acetaminophen + Codeine is a classic combination analgesic widely used worldwide for moderate to moderately severe pain management. However, the TxGNN model returned no repurposing predictions for this combination drug entry, likely because the pipeline requires a single-ingredient DrugBank mapping that could not be resolved. Without a prediction target, this report documents the data gaps that must be resolved before a full repurposing evaluation can proceed.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Unknown (no TFDA license records found; combination not registered in this system) |
| Predicted New Indication | None — TxGNN returned no predictions |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 (model prediction only — and none was produced) |
| US Market Status | 未上市 (Not marketed in Taiwan; US status not queried) |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
No prediction was generated, so a mechanistic bridge analysis cannot be completed.
Based on general pharmacological knowledge: Acetaminophen acts centrally and peripherally to inhibit prostaglandin synthesis (COX pathway), producing analgesia and antipyresis without significant anti-inflammatory effects at standard doses. Codeine is a prodrug converted to morphine via CYP2D6, acting on μ-opioid receptors to modulate pain perception. Together, they provide additive analgesia for moderate pain that is suboptimal for either agent alone.
TxGNN’s knowledge graph operates on single-ingredient nodes mapped to DrugBank IDs. Because this entry is a multi-ingredient combination (ACETAMINOPHEN; CODEINE) without a resolved DrugBank ID, the prediction engine could not anchor to a graph node — resulting in zero outputs. Separating the two ingredients and running individual predictions would be the appropriate remediation.
Clinical Trial Evidence
Currently no related clinical trials registered (no predicted indication target to query against).
Literature Evidence
Currently no related literature available (no predicted indication target to query against).
US Market Information
No Taiwan license records found for this combination entry. The query returned 0 results from the TFDA database.
Note: Acetaminophen + Codeine products are widely marketed internationally (e.g., Tylenol with Codeine No. 3/4 in the US under NDA 022450 and others), but this system did not retrieve those records. A direct US FDA query is recommended.
Safety Considerations
Please refer to the package insert for safety information.
Known class-level concerns for Acetaminophen + Codeine combinations include:
- Codeine (opioid): Risk of respiratory depression, dependence, and CYP2D6 ultra-rapid metabolizer toxicity; contraindicated in children post-tonsillectomy (FDA Black Box Warning issued 2013).
- Acetaminophen: Hepatotoxicity risk with overdose or concurrent alcohol use; maximum daily dose 4 g (3 g in high-risk patients).
- DDI query: Returned
not_found— formal interaction screening could not be completed.
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN pipeline produced zero repurposing predictions because the combination drug entry could not be mapped to a DrugBank node — the fundamental input required for graph-based prediction is missing. There is no prediction to evaluate.
To proceed, the following is needed:
- Split the combination into individual components: Run separate TxGNN analyses for
ACETAMINOPHEN(DrugBank: DB00316) andCODEINE(DrugBank: DB00318) to obtain individual predictions - Resolve DrugBank ID: Confirm whether a combination-level DrugBank entry exists, or confirm the two-component approach above
- Retrieve US FDA records: Query openFDA NDA database directly for Acetaminophen+Codeine products to populate the regulatory table
- Obtain MOA data: Pull structured pharmacology from DrugBank API for both components (Data Gap DG002)
- Obtain safety/warning data: Download and parse prescribing information to fill DG001 (Blocking severity)
- Re-run evidence collection: Once a predicted indication is established, re-run ClinicalTrials.gov and PubMed collectors against the new target
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.